(Alliance News) - AstraZeneca PLC on Monday said it will present new data on cardiovascular and renal disease drugs in the US between Thursday and Monday next week.
Renal is the adjective for kidneys in animals and humans.
Over 60 abstracts across its Cardiovascular, Renal & Metabolism portfolio and Astra's rare disease group Alexion will be shown at the American Society of Nephrology Kidney Week from November 3 to November 6 in Orlando, Florida and the American Heart Association Scientific Sessions from November 5 to November 7 in Chicago, Illinois.
Among drugs with new data are cardiovascular drug Farxiga and Lokelma, which treats hyperkalaemia, which is characterised by high levels of potassium in the blood.
New subgroup data on Farxiga will show how Farxiga helps prevent or slow the progression of chronic kidney disease in a "large" patient population.
AstraZeneca shares were 0.3% lower at 10,098 pence each in London on Monday afternoon.
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)